The Pet Industry's Leading Resource for News & Content Distribution

BodeVet Partners with Leading Veterinary Organizations to Support its Launch of StablePlate RX®

ROCKVILLE, MD. (March 22, 2018) – BodeVet, a developer of advanced transfusion treatment options for the veterinary industry, announced it has partnered with Blue Ridge Veterinary Blood Bank, HemoSolutions and Northwest Veterinary Blood Bank to support the distribution of its first product, StablePlate RX® – the world’s first injectable freeze-dried platelet derived product.

“After years of research and development, we’re pleased to align with these partners to offer veterinary specialists and general practitioners access to StablePlate RX CANINE for the treatment of acute uncontrolled hemorrhage in bleeding canine patients,” said Anne Hale, DVM, Chief Technical Officer at BodeVet. “We look forward to continuing our relationships with these distributors to make the product widely available in the United States to meet the growing demand for blood products in the veterinary market.”

Its distributors are also enthusiastic about partnering with BodeVet to make StablePlate RX accessible to pet owners.

“HemoSolutions, a provider of quality blood products for the veterinary profession, is proud to be a distributor of StablePlateRX,” said Teresa Ritz of HemoSolutions. “The shelf-stable platelets that BodeVet provides are a great addition to our line of life saving products.”

BodeVet also aligned with Blue Pearl Veterinary Partners, Friendship Animal Hospital, Cornell University, University of GA and Iowa State University last year to test the efficacy and safety of StablePlate RX CANINE in clinical trials. Ethos Veterinary Health and North Carolina State University are joining the clinical trial group this month. Those findings will be revealed later this year as part of its 1-2017-K9 study.

For more information on BodeVet, StablePlate RX or its team of experts in veterinary transfusion medicine, visit www.bodevet.com.

About BodeVet

BodeVet, Inc., a wholly owned subsidiary of Cellphire, Inc., is staffed and advised by world leaders in veterinary transfusion medicine. Formed in 2015, BodeVet’s mission is to promote animal health and welfare by developing and delivering new treatment solutions to veterinary medical practitioners. The company uses technology borrowed from Cellphire, a biotechnology company established in early 2006, to develop novel blood products for use in hemostasis and regenerative medicine in veterinary medicine.

# # #

Media Contact:
Mackenzie Smith
Mackenzie.smith@fetchingcommunications.com
(877) 703.3824 x106

Get Your News in the Hands of Journalists Focused on the Pet Industry

Don't delay. Order your press release today!

Pin It on Pinterest

CONTACT US